Experimental models of lung, skin, heart, and liver fibrosis demonstrate that genetic deletion of CD44, its pharmacological blockade, or inhibition of HA biosynthesis leads to inhibition of the progression of fibrogenic changes. Here, CD44 is linked to Hepatic fibrosis.